2 . ) To observe the fate of LNL-6 vector when introduced into 
normal bone marrow cells during AuBMT . 
3 . ) To evaluate the safety of retroviral-mediated gene 
transfer (RMGT) as a method of marking autologous 
cells in the setting of AuBMT. 
3.0. PATIENT SELECTION 
Each referred patient will be considered individually 
with careful review of past history and present status. 
The referring physician, the attending BMT physician, 
patient, and family members will make a joint decision 
regarding further treatment based on both short and long 
term benefits and risks of autologous bone marrow 
transplantation as compared to conventional therapy. 
After the decision to undergo AuBMT is made, the proposed 
protocol will then be offered to the patient. The 
patient's decision to participate or decline RMGT will 
not modify the type or time of AuBMT. 
3.1) Criteria for Patient Eligibility 
3.11) Patients who have harvested and stored 
marrow sufficient for transplantation (>2 
x 10 8 nucleated cells/kg) obtained during 
a complete remission (see 5.1 - Criteria 
for Marrow Harvest) . 
3.12) Patients with histologic confirmation of 
the following diseases are eligible: 
Acute myelogenous or acute lymphocytic 
leukemia in second or greater remission 
Acute myelogenous or acute lymphocytic 
leukemia in early relapse, defined as 
<30% marrow blasts 
Refractory acute myelogenous or acute 
lymphocytic leukemia with less that 10% 
marrow blasts 
3.13) Patients must be greater than or equal to 
18 years but less than or equal to 65 
years of age. 
3.14) Patients must be able to give informed 
consent. 
[472] 
Recombinant DNA Research, Volume 15 
